vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and WYNDHAM HOTELS & RESORTS, INC. (WH). Click either name above to swap in a different company.
WYNDHAM HOTELS & RESORTS, INC. is the larger business by last-quarter revenue ($334.0M vs $284.0M, roughly 1.2× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -18.0%, a 114.3% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs -76.3%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs -4.6%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Wyndham Hotels & Resorts, Inc., is an American hospitality company based in Parsippany, New Jersey, United States. It describes itself as the largest hotel franchisor in the world, with 9,100 locations.
ACAD vs WH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $334.0M |
| Net Profit | $273.6M | $-60.0M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | — |
| Net Margin | 96.3% | -18.0% |
| Revenue YoY | 9.4% | -76.3% |
| Net Profit YoY | 90.3% | -170.6% |
| EPS (diluted) | $1.61 | $-0.80 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $334.0M | ||
| Q4 25 | $284.0M | $334.0M | ||
| Q3 25 | $278.6M | $382.0M | ||
| Q2 25 | $264.6M | $397.0M | ||
| Q1 25 | $244.3M | $316.0M | ||
| Q4 24 | $259.6M | $336.0M | ||
| Q3 24 | $250.4M | $396.0M | ||
| Q2 24 | $242.0M | $367.0M |
| Q1 26 | — | $-60.0M | ||
| Q4 25 | $273.6M | $-60.0M | ||
| Q3 25 | $71.8M | $105.0M | ||
| Q2 25 | $26.7M | $87.0M | ||
| Q1 25 | $19.0M | $61.0M | ||
| Q4 24 | $143.7M | $85.0M | ||
| Q3 24 | $32.8M | $102.0M | ||
| Q2 24 | $33.4M | $86.0M |
| Q1 26 | — | — | ||
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — |
| Q1 26 | — | — | ||
| Q4 25 | 6.1% | -11.4% | ||
| Q3 25 | 12.8% | 46.6% | ||
| Q2 25 | 12.2% | 37.8% | ||
| Q1 25 | 7.9% | 35.4% | ||
| Q4 24 | 59.1% | 38.4% | ||
| Q3 24 | 12.6% | 43.2% | ||
| Q2 24 | 12.6% | 39.5% |
| Q1 26 | — | -18.0% | ||
| Q4 25 | 96.3% | -18.0% | ||
| Q3 25 | 25.8% | 27.5% | ||
| Q2 25 | 10.1% | 21.9% | ||
| Q1 25 | 7.8% | 19.3% | ||
| Q4 24 | 55.4% | 25.3% | ||
| Q3 24 | 13.1% | 25.8% | ||
| Q2 24 | 13.8% | 23.4% |
| Q1 26 | — | $-0.80 | ||
| Q4 25 | $1.61 | $-0.77 | ||
| Q3 25 | $0.42 | $1.36 | ||
| Q2 25 | $0.16 | $1.13 | ||
| Q1 25 | $0.11 | $0.78 | ||
| Q4 24 | $0.86 | $1.06 | ||
| Q3 24 | $0.20 | $1.29 | ||
| Q2 24 | $0.20 | $1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $64.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $468.0M |
| Total Assets | $1.6B | $4.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $64.0M | ||
| Q4 25 | $177.7M | $64.0M | ||
| Q3 25 | $258.0M | $70.0M | ||
| Q2 25 | $253.6M | $50.0M | ||
| Q1 25 | $217.7M | $48.0M | ||
| Q4 24 | $319.6M | $103.0M | ||
| Q3 24 | $155.1M | $72.0M | ||
| Q2 24 | $177.1M | $70.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | $2.5B | ||
| Q3 25 | — | $2.6B | ||
| Q2 25 | — | $2.5B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.4B | ||
| Q2 24 | — | $2.4B |
| Q1 26 | — | $468.0M | ||
| Q4 25 | $1.2B | $468.0M | ||
| Q3 25 | $917.3M | $583.0M | ||
| Q2 25 | $822.4M | $570.0M | ||
| Q1 25 | $765.2M | $579.0M | ||
| Q4 24 | $732.8M | $650.0M | ||
| Q3 24 | $577.2M | $583.0M | ||
| Q2 24 | $516.7M | $623.0M |
| Q1 26 | — | $4.2B | ||
| Q4 25 | $1.6B | $4.2B | ||
| Q3 25 | $1.3B | $4.3B | ||
| Q2 25 | $1.2B | $4.3B | ||
| Q1 25 | $1.1B | $4.2B | ||
| Q4 24 | $1.2B | $4.2B | ||
| Q3 24 | $976.9M | $4.2B | ||
| Q2 24 | $914.1M | $4.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | 5.37× | ||
| Q3 25 | — | 4.43× | ||
| Q2 25 | — | 4.44× | ||
| Q1 25 | — | 4.29× | ||
| Q4 24 | — | 3.72× | ||
| Q3 24 | — | 4.19× | ||
| Q2 24 | — | 3.83× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | $367.0M |
| Free Cash FlowOCF − Capex | — | $168.0M |
| FCF MarginFCF / Revenue | — | 50.3% |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $437.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $367.0M | ||
| Q4 25 | $-48.7M | $152.0M | ||
| Q3 25 | $74.3M | $86.0M | ||
| Q2 25 | $64.0M | $70.0M | ||
| Q1 25 | $20.3M | $59.0M | ||
| Q4 24 | $40.4M | $134.0M | ||
| Q3 24 | $63.2M | $79.0M | ||
| Q2 24 | $25.0M | $1.0M |
| Q1 26 | — | $168.0M | ||
| Q4 25 | — | $136.0M | ||
| Q3 25 | $73.9M | $75.0M | ||
| Q2 25 | — | $58.0M | ||
| Q1 25 | — | $52.0M | ||
| Q4 24 | — | $109.0M | ||
| Q3 24 | $63.2M | $71.0M | ||
| Q2 24 | — | $-6.0M |
| Q1 26 | — | 50.3% | ||
| Q4 25 | — | 40.7% | ||
| Q3 25 | 26.5% | 19.6% | ||
| Q2 25 | — | 14.6% | ||
| Q1 25 | — | 16.5% | ||
| Q4 24 | — | 32.4% | ||
| Q3 24 | 25.2% | 17.9% | ||
| Q2 24 | — | -1.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.8% | ||
| Q3 25 | 0.1% | 2.9% | ||
| Q2 25 | — | 3.0% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 7.4% | ||
| Q3 24 | 0.0% | 2.0% | ||
| Q2 24 | — | 1.9% |
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | — | ||
| Q3 25 | 1.03× | 0.82× | ||
| Q2 25 | 2.40× | 0.80× | ||
| Q1 25 | 1.07× | 0.97× | ||
| Q4 24 | 0.28× | 1.58× | ||
| Q3 24 | 1.93× | 0.77× | ||
| Q2 24 | 0.75× | 0.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
WH
| Fee-related and other revenues | $334.0M | 100% |
| Management and other fees | $2.0M | 1% |
